실시간 바이오 인텔리전스 · ADC · CGT

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

8,428+프로그램
40+FDA 승인
3,743+모집 중
ADC 1032·Antibody 4683·CGT 2713차세대 추천 →·Data Tier →
8428프로그램40FDA 승인
751오늘 방문
11,391누적 방문
7303갱신 대기S–CData TierS/A/B차세대→Insight1032HER2 breast4683Antibody2713CGT→Psoriasis→NSCLC40FDA 승인
피드Data Tier차세대Insight

추천 비교

비교 도구 →
HER2 ADCEnhertu · Kadcyla · RC48CD19 CAR-TYescarta · KymriahPD-1Keytruda · Opdivo다발골수종Darzalex · BlenrepTROP2 ADCTrodelvy · Dato-DXd · SGNectin-4 · TROP2Padcev · Trodelvy건선 IL pathwayStelara · Cosentyx · SkyriziAnti-VEGF (안과)Eylea · LucentisAnti-TNFHumira · EnbrelIL-12/23Stelara · Skyrizi아토피·IL-13Dupixent · EbglyssPCSK9 · LDLRepatha · Praluent · LeqvioGLP-1 · incretinSemaglutide · Tirzepatide혈우병 유전자치료Hemgenix · Roctavian겸상적혈구 CGTCasgevy · Lyfgenia망막·DMD 유전자치료Luxturna · Elevidys

빠른 검색 · 이슈 태그

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
다음 갱신 D-5 · 마지막 7월 21일
AntibodystaleGenentech, Inc.Phase 1

MetMAb (MetMAb)

Solid Cancers · Solid Cancers

#SolidCancers#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleChinese PLA General HospitalPhase 2

oxaliplatin+capecitabine+bevacizumab+PD-1 antibody (oxaliplatin+capecitabine+bevacizumab+PD-1 antibody)

Colorectal Cancer; RAS Mutation · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleBeiGenePhase 2

Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine (Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine)

Tislelizumab; Bevacizumab · Tislelizumab

#Tislelizumab#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRadboud University Medical Cent…Preclinical

111Indium-bevacizumab (111Indium-bevacizumab)

Clear Cell Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma

#ClearCellRenalCellCarcinoma#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleBeijing Biostar Pharmaceuticals…Phase 2

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Non-small Cell Lung Cancer Patients with Brain Metastases · Non-small Cell Lung Cancer Patients with

#Non-smallCellLungCancerPatientsw#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleHunan Province Tumor HospitalPhase 2

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleWomen's Hospital School Of Medi…Phase 2

PD-1 inhibitor， bevacizumab (PD-1 inhibitor， bevacizumab)

Gestational Trophoblastic Neoplasia · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleGlaxoSmithKlinePreclinical

sunitinib, sorafenib, bevacizumab, and pazopanib (Targeted agents indicated in management of advanced/metastatic RCC, Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib))

Carcinoma, Renal Cell · Carcinoma, Renal Cell

#CarcinomaRenalCell#Antibody#Preclinical#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleFudan UniversityPhase 2

Faminitib or bevacizumab (Faminitib or bevacizumab)

Pancreatic Cancer · Pancreatic Cancer

#PancreaticCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodyBiologicstaleHenan Provincial People's Hospi…Preclinical

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

Genetic Change · Genetic Change

#GeneticChange#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAsan Medical CenterApproved

TDM-based infliximab intravenous therapy (TDM-based infliximab intravenous therapy)

Crohn Disease; Infliximab · Crohn Disease

#CrohnDisease#Antibody#Approved#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleSamsung Bioepis Co., Ltd.Phase 3

proposed biosimilar to infliximab (SB2, SB2 (proposed biosimilar to infliximab))

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleInstitute for Clinical and Expe…Preclinical

MabCampath, (MabCampath,)

Kidney Transplantation · Kidney Transplantation

#KidneyTransplantation#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleGlostrup University Hospital, C…Approved

etanercept or adalimumab (Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity, Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab))

SPONDYLOARTHRITIS · SPONDYLOARTHRITIS

#SPONDYLOARTHRITIS#Antibody#Approved#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleUniversity of Illinois at Chica…Phase 3

Elra (Elranatamab, Elranatamab (Elra))

Plasmablastic Lymphoma; Hiv · Plasmablastic Lymphoma

#PlasmablasticLymphoma#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

Amivantamab and Recombinant Human Hyaluronidase (Amivantamab and Recombinant Human Hyaluronidase)

Locally Recurrent Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma · Locally Recurrent Skin Squamous Cell Car

#LocallyRecurrentSkinSquamousCell#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleChinese PLA General HospitalPhase 2

metoprolol, infliximab, etanercept, tocilizumab and/or other agents (metoprolol, infliximab, etanercept, tocilizumab and/or other agents)

Solid Tumor; Hematological Malignancy · Solid Tumor

#SolidTumor#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleInstitut für Klinische Krebsfor…Phase 2

Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy (Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy)

Relapsed /Refractory DLBCL · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleZhejiang Cancer HospitalPhase 2

Recombinant human adenovirus type 5＋Camrelizumab (Recombinant human adenovirus type 5＋Camrelizumab)

Uterine Cervical Neoplasms; Oncolytic Virotherapy · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
ADCBiologicstaleUnion Hospital, Tongji Medical …Phase 2

SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel (SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstalePfizerPreclinical

GO (Gemtuzumab Ozogamicin, Gemtuzumab Ozogamicin (GO))

Leukemia, Myeloid, Acute · Leukemia, Myeloid, Acute

#LeukemiaMyeloidAcute#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 ACTIVE
ADCBiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan-nxki)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 71.7%임상시험 1상태 RECRUITING
ADCBiologicstaleTallac TherapeuticsPhase 2

TAC-001 (TAC-001)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleTORL Biotherapeutics, LLCPhase 1

TORL-4-500 (TORL-4-500)

Advanced Solid Tumor; Hepatocellular Carcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleJiangsu Alphamab Biopharmaceuti…Phase 1

JSKN022 (JSKN022)

Advanced Malignant Solid Tumors · Advanced Malignant Solid Tumors

#AdvancedMalignantSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING

86 / 142 페이지

← 이전다음 →
전체 8,428개 프로그램 보기